Safety of bi-weekly infusion of A1-PI augmentation therapy in RAPID Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015
LATE-BREAKING ABSTRACT: Long-term efficacy of A1-PI therapy in RAPID and RAPID extension trials Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015
Long-term efficacy of A1 -PI therapy in RAPID and its extension study Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014
External assessment and validation of the RAPID score using an international multicentre pleural infection cohort treated with intrapleural fibrinolytics Source: Virtual Congress 2021 – Respiratory infections and bronchiectasis outcomes Year: 2021
Effect of exacerbations on lung density in alpha-1 antitrypsin deficiency: Subgroup analysis of the RAPID trial programme Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond Year: 2018
Prospective validation of the RAPID clinical risk prediction score in adult patients with pleural infection: the PILOT study Source: Eur Respir J, 56 (5) 2000130; 10.1183/13993003.00130-2020 Year: 2020
Pragmatic global dosing recommendations for the 3-month, once-weekly rifapentine and isoniazid preventive TB regimen in children Source: Eur Respir J, 57 (1) 2001756; 10.1183/13993003.01756-2020 Year: 2021
Safety of bi-weekly intravenous therapy with alpha-1 antitrypsin Source: International Congress 2017 – Clinical challenges in chronic lung diseases Year: 2017
Clinical and economic outcomes following 52-week add-on omalizumab Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013
Safety and efficacy of NVA237 once daily in Japanese patients: The GLOW4 trial Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012
Response to mepolizumab treatment is sustained across 4-weekly dosing periods Source: ERJ Open Res, 6 (3) 00068-2020; 10.1183/23120541.00068-2020 Year: 2020
RAPID lung cancer diagnostic and care pathway from referral to treatment Source: Virtual Congress 2020 – Management issues in thoracic oncology Year: 2020
Safety and tolerability of indacaterol over 52 weeks of treatment in COPD Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Efficacy and safety of indacaterol 150 μg once-daily in COPD: a 12-week study Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Adherence to 6-month FDC Budesonide/Formoterol treatment and Quality of Life in Greek asthmatic patients-COMPLETE study Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020
Late Breaking Abstract - Prolonged azithromycin maintenance treatment in patients with COPD, a follow-up of the COLUMBUS trial Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019
Safety and acceptability of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
Safety and tolerability of multiple-dose indacaterol, a novel 24-hour β2 -agonist, in patients with mild asthma Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005
Dupilumab Efficacy in Asthma Patients With FEV1 60–80% Predicted on Medium-Dose ICS: LIBERTY ASTHMA QUEST Study Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019
BREEZE: Open-label, Clinical Study to Evaluate the Safety and Tolerability of a Treprostinil Dry Powder Inhaler in Patients with Pulmonary Arterial Hypertension Currently Using Tyvaso Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021